润燥止痒胶囊联合常规疗法治疗寻常型银屑病的系统评价

Systematic Evaluation of Runzao Zhiyang Capsules Combined with Conventional Therapy in the Treatment of Psoriasis Vulgaris

目的:评价润燥止痒胶囊联合常规疗法治疗寻常型银屑病的疗效性及安全性。方法:检索PubMed、Embase、中国知网和维普数据库等,收集截至2022年2月有关润燥止痒胶囊联合常规疗法治疗寻常型银屑病的随机对照试验。采用RevMan 5.3、Stata 15.0软件进行Meta分析,对临床有效率进行试验序贯分析(TSA)。结果:共纳入16项研究,合计1 275例患者。Meta分析结果显示,润燥止痒胶囊联合常规疗法可提高患者的临床有效率(RR=1.37,95%CI=1.28~1.47,P<0.000 01),降低银屑病皮损面积和严重指数评分(MD=-2.71,95%CI=-3.55~-1.88,P<0.000 01)及复发率(RR=0.35,95%CI=0.22~0.55,P<0.000 01),与单纯使用常规疗法比较,差异均有统计学意义;两组治疗方案的不良反应发生率比较,差异无统计学意义(RR=0.46,95%CI=0.32~0.66,P<0.000 1);TSA结果进一步证实临床有效率的证据确切。结论:润燥止痒胶囊联合常规疗法治疗寻常型银屑病疗效显著,且安全性良好,但仍需大样本、多中心的随机对照试验进一步验证。

OBJECTIVE: To evaluate the efficacy and safety of Runzao Zhiyang capsules combined with conventional therapy in the treatment of psoriasis. METHODS: Retrieved from PubMed, EMbase, CNKI and VIP etc., randomized controlled trials about Runzao Zhiyang capsule in the treatment of psoriasis vulgaris were collected until Feb. 2022. Meta-analysis was performed by using RevMan 5.3 and Stata 15.0 software, and trial sequential analysis(TSA) was conducted for clinical response rate. RESULTS: A total of 16 studies were included, involving 1 275 patients. Meta-analysis results showed that Runzao Zhiyang capsules combined with conventional therapy could improve the clinical effective rate(RR=1.37,95%CI=1.28-1.47,P<0.000 01), reduced PASI score(MD=-2.71,95%CI=-3.55--1.88,P<0.000 01) and the recurrence rate(RR=0.35,95%CI=0.22-0.55,P<0.000 01), and there was statistical significance, compared with conventional therapy alone. There was no statistical significance in the incidence of adverse reactions between two groups(RR=0.46,95%CI=0.32-0.66,P<0.000 1). The results of TSA further confirmed the evidence of clinical effective rate. CONCLUSIONS: Runzao Zhiyang capsules combined with conventional therapy is effective and safe in the treatment of psoriasis vulgaris, but the above results still need more large-scale and multi-center RCTs for further confirmation.